These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 29958106)
21. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215 [TBL] [Abstract][Full Text] [Related]
22. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588 [TBL] [Abstract][Full Text] [Related]
23. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Wijmenga C; Gregory PE; Hajra A; Schröck E; Ried T; Eils R; Liu PP; Collins FS Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1630-5. PubMed ID: 8643682 [TBL] [Abstract][Full Text] [Related]
24. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131 [TBL] [Abstract][Full Text] [Related]
25. Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice. Kuo YH; Zaidi SK; Gornostaeva S; Komori T; Stein GS; Castilla LH Blood; 2009 Apr; 113(14):3323-32. PubMed ID: 19179305 [TBL] [Abstract][Full Text] [Related]
26. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Kummalue T; Lou J; Friedman AD Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730 [TBL] [Abstract][Full Text] [Related]
27. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Yu M; Mazor T; Huang H; Huang HT; Kathrein KL; Woo AJ; Chouinard CR; Labadorf A; Akie TE; Moran TB; Xie H; Zacharek S; Taniuchi I; Roeder RG; Kim CF; Zon LI; Fraenkel E; Cantor AB Mol Cell; 2012 Feb; 45(3):330-43. PubMed ID: 22325351 [TBL] [Abstract][Full Text] [Related]
28. Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia. Kim H; Tan TK; Lee DZY; Huang XZ; Ong JZL; Kelliher MA; Yeoh AEJ; Sanda T; Tan SH Leukemia; 2024 Sep; 38(9):1906-1917. PubMed ID: 38969731 [TBL] [Abstract][Full Text] [Related]
29. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703 [TBL] [Abstract][Full Text] [Related]
30. CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Britos-Bray M; Ramirez M; Cao W; Wang X; Liu PP; Civin CI; Friedman AD Blood; 1998 Dec; 92(11):4344-52. PubMed ID: 9834241 [TBL] [Abstract][Full Text] [Related]
31. The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation. Cao W; Adya N; Britos-Bray M; Liu PP; Friedman AD J Biol Chem; 1998 Nov; 273(47):31534-40. PubMed ID: 9813068 [TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086 [TBL] [Abstract][Full Text] [Related]
33. Cbfbeta-SMMHC impairs differentiation of common lymphoid progenitors and reveals an essential role for RUNX in early B-cell development. Kuo YH; Gerstein RM; Castilla LH Blood; 2008 Feb; 111(3):1543-51. PubMed ID: 17940206 [TBL] [Abstract][Full Text] [Related]
34. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias. Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670 [TBL] [Abstract][Full Text] [Related]
35. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298 [TBL] [Abstract][Full Text] [Related]
36. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
37. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Conrad RJ; Fozouni P; Thomas S; Sy H; Zhang Q; Zhou MM; Ott M Mol Cell; 2017 Sep; 67(6):1001-1012.e6. PubMed ID: 28844864 [TBL] [Abstract][Full Text] [Related]
38. Emerging therapies for inv(16) AML. Surapally S; Tenen DG; Pulikkan JA Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975 [TBL] [Abstract][Full Text] [Related]
39. The PEBP2beta/CBF beta-SMMHC chimeric protein is localized both in the cell membrane and nuclear subfractions of leukemic cells carrying chromosomal inversion 16. Kanto S; Chiba N; Tanaka Y; Fujita S; Endo M; Kamada N; Yoshikawa K; Fukuzaki A; Orikasa S; Watanabe T; Satake M Leukemia; 2000 Jul; 14(7):1253-9. PubMed ID: 10914550 [TBL] [Abstract][Full Text] [Related]
40. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]